News Releases

Allerject™ now covered by public and private insurance plans across Canada

Laval - Sanofi is pleased to report that Allerject™ – the new epinephrine auto-injector available in Canada – has been listed on all public reimbursement formularies across Canada. Allerject™ has also been approved for listing on the Non-Insured Health Benefits (NIHB) program which provides coverage to the First Nations and Inuit population.

“We are pleased with the positive formulary listings for Allerject™, as it is an important step for patient access and choice for those living with severe, life-threatening allergies” says Jon Fairest, President and CEO of Sanofi Canada.

In addition, approximately 97% of private insurance plans cover Allerject, adding to the accessibility of Allerject to people living with anaphylaxis in Canada.

Allerject™ was designed to address unmet patient needs and make a positive difference in the lives of those with severe allergies. It is the first epinephrine auto-injector with automated voice instructions designed to help people correctly use the device. Allerject™ ‘talks’ people step-by-step through the injection process.

For more information about Allerject™, please visit www.allerject.ca.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi companies in Canada include Sanofi Canada (pharmaceuticals), Sanofi Pasteur (vaccines), Sanofi Consumer Health (health and beauty), Genzyme (rare diseases) and Merial (animal health). Together they employ more than 1,700 people across the country. In 2012 Sanofi companies invested $122 million in R&D in Canada, creating jobs, business and opportunity throughout the country.